Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Norethandrolone→

Norethandrolone Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
52-78-8
Molecular formula
C20H30O2
Molecular weight
302.5 g/mol
Drug class
Synthetic anabolic-androgenic steroid17-alpha-alkylated androgen receptor agonist
Mechanism of action
Activates androgen receptors and alters androgen-responsive gene transcription, producing anabolic effects on protein synthesis and erythropoiesis. It is a synthetic 17-alpha-alkylated testosterone derivative.
Indications / reported uses
  • Historically used for selected hypoplastic and aplastic anaemias and other bone-marrow failure disorders; use is specialist and jurisdiction-specific, with significant hepatic and androgenic safety concerns.

Sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC10905082/ · https://pubchem.ncbi.nlm.nih.gov/#query=norethandrolone · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Norethandrolone Environmental Risk Assessment (ERA) (the Norethandrolone ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.